BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23537297)

  • 1. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
    Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F
    J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleural sarcomatoid malignant mesothelioma consisting of histiocytoid cells.
    Kawahara K; Nagano T; Matsui K; Kawai T; Iwasaki T
    Pathol Int; 2007 Apr; 57(4):229-31. PubMed ID: 17316420
    [No Abstract]   [Full Text] [Related]  

  • 4. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
    Gill RR; Umeoka S; Mamata H; Tilleman TR; Stanwell P; Woodhams R; Padera RF; Sugarbaker DJ; Hatabu H
    AJR Am J Roentgenol; 2010 Aug; 195(2):W125-30. PubMed ID: 20651171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
    Sherman ME; Mark EJ
    Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
    Bueno R; Reblando J; Glickman J; Jaklitsch MT; Lukanich JM; Sugarbaker DJ
    Ann Thorac Surg; 2004 Nov; 78(5):1774-6. PubMed ID: 15511473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma.
    Tsuta K; Kato Y; Tochigi N; Hoshino T; Takeda Y; Hosako M; Maeshima AM; Asamura H; Kondo T; Matsuno Y
    Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):126-30. PubMed ID: 19516197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
    Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
    Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
    Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
    J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
    Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
    Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current problems in the diagnosis of malignant pleural mesothelioma].
    Hosokawa Y; Matsuge S; Hayashi K; Tao Y; Nakno R; Kemmochi Y; Ishimine A; Murakami Y; Kano S
    Kyobu Geka; 2007 Jan; 60(1):14-8. PubMed ID: 17249532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM; Franke FE; Müller KM
    Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
    Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.